OncoMatch/Clinical Trials/NCT04170946
Talazoparib and Thoracic RT for ES-SCLC
Is NCT04170946 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for lung cancer.
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy. Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage EXTENSIVE DISEASE
Metastatic disease required
Documented extensive disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — induction
Completion of induction chemotherapy, 4-6 cycles of a platinum agent and etoposide.
Must have received: etoposide — induction
Completion of induction chemotherapy, 4-6 cycles of a platinum agent and etoposide.
Cannot have received: PARP inhibitor (talazoparib)
Any previous treatment with PARP inhibitor, including talazoparib.
Cannot have received: thoracic radiotherapy
Exception: prior breast RT is permitted
Previous radiotherapy to thorax (prior breast RT is permitted).
Cannot have received: allogenic bone marrow transplant or double umbilical cord blood transplantation
Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify